{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:49:27Z","timestamp":1792442967670,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM), and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant-eligible (TE) NDMM. HR cytogenetics were defined by presence of del(17p), t(4;14), and\/or t(14;16). Treatment consisted of daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance. The primary end point was feasibility. Fifty patients with previously untreated NDMM were included. Median age was 57. Del(17p), t(4;14), and t(14;16) were found in 40%, 52%, and 20% of patients, respectively. At data cutoff, the study met the primary end point with 36 patients completing second transplant. Twenty patients discontinued the study due to stem cell collection failure (n\u00a0= 8), disease progression (n\u00a0= 7), adverse event (n\u00a0= 4), or consent withdrawal (n\u00a0= 1). Grade 3 to 4 D-KRd induction\/consolidation\u2013related adverse events (&amp;gt;5% of patients) were neutropenia (39%), anemia (12%), thrombocytopenia (7%), and infection (6%). The overall response rate was 100% for patients completing second transplant, including 81% complete response. Premaintenance minimal residual disease (MRD) negativity rate (10\u20136) was 94%. After a median follow-up of 33 months, the 30-month progression-free survival (PFS) and overall survival were 80% and 91%, respectively. In conclusion, D-KRd with tandem transplant is feasible in patients with HR TE-NDMM and resulted in high response rates and PFS. This trial was registered at www.clinicaltrials.gov as #NCT03606577.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023597","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T21:47:15Z","timestamp":1708724835000},"page":"2029-2036","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma"],"prefix":"10.1182","volume":"143","author":[{"given":"Cyrille","family":"Touzeau","sequence":"first","affiliation":[{"name":"1Service d\u2019h\u00e9matologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France"},{"name":"2Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers (CRCI2NA), INSERM, Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 d'Angers, Universit\u00e9 de Nantes, Nantes, France"},{"name":"3Site de Recherche Int\u00e9gr\u00e9e sur le Cancer (SIRIC) \u201cImaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD),\u201d Institut National du Cancer-Direction G\u00e9n\u00e9rale de l'Offre de Soins (INCA-DGOS)-Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) 12558, Nantes-Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), Service d\u2019H\u00e9matologie, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"5Service d\u2019h\u00e9matologie, H\u00f4pital Haut-L\u00e9v\u00eaque, CHU de Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"6Maladies du Sang, CHRU de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"7Service d\u2019h\u00e9matologie, CHU de Caen, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lorraine","family":"Chretien","sequence":"additional","affiliation":[{"name":"8H\u00e9matologie Clinique, CHU Dijon Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"9H\u00f4pital Lyon Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre","sequence":"additional","affiliation":[{"name":"10Service d\u2019h\u00e9matologie, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jacquet","sequence":"additional","affiliation":[{"name":"11Service d\u2019h\u00e9matologie, CHU de Nancy, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tiab","sequence":"additional","affiliation":[{"name":"12Service d\u2019h\u00e9matologie, Centre Hospitalier Departemental, La Roche sur Yon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"13Service d\u2019h\u00e9matologie, CHU de Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), Service d\u2019H\u00e9matologie, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-0934","authenticated-orcid":false,"given":"Alexandra","family":"Jobert","sequence":"additional","affiliation":[{"name":"14D\u00e9partement de recherche clinique, CHU Hotel Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Planche","sequence":"additional","affiliation":[{"name":"14D\u00e9partement de recherche clinique, CHU Hotel Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Universit\u00e9 de Toulouse, Universit\u00e9 Paul Sabatier (UPS), Service d\u2019H\u00e9matologie, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"1Service d\u2019h\u00e9matologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France"},{"name":"2Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers (CRCI2NA), INSERM, Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 d'Angers, Universit\u00e9 de Nantes, Nantes, France"},{"name":"3Site de Recherche Int\u00e9gr\u00e9e sur le Cancer (SIRIC) \u201cImaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD),\u201d Institut National du Cancer-Direction G\u00e9n\u00e9rale de l'Offre de Soins (INCA-DGOS)-Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) 12558, Nantes-Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2024051615204418500_bib1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2024051615204418500_bib2","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024051615204418500_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/bjh.17488","article-title":"No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and\/or t(4;14) over the two past decades","volume":"194","author":"Chalopin","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2024051615204418500_bib4","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"2024051615204418500_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024051615204418500_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10192","key":"2024051615204418500_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"2024051615204418500_bib8","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024051615204418500_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024051615204418500_bib10","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and\u00a0lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2024051615204418500_bib11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"2024051615204418500_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2024051615204418500_bib13","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024051615204418500_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024051615204418500_bib15","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024051615204418500_bib16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"issue":"25","key":"2024051615204418500_bib17","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024051615204418500_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncr.31718","article-title":"Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024051615204418500_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2005-06-2573","article-title":"Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol","volume":"107","author":"Moreau","year":"2006","journal-title":"Blood"},{"issue":"25","key":"2024051615204418500_bib20","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024051615204418500_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2024051615204418500_bib22","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab\u00a0+ bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2024051615204418500_bib23","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab\u2212 and lenalidomide\u2212 containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2024051615204418500_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and\u00a0unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/20\/2029\/2225543\/blood_bld-2023-023597-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/20\/2029\/2225543\/blood_bld-2023-023597-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:21:05Z","timestamp":1715872865000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/20\/2029\/515075\/Daratumumab-carfilzomib-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":24,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,5,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023597","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}